BRAF inhibitors (BRAFis) can inhibit the driving effect of hypoxia-induced factor 1α (HIF1α) and Myc on glycolysis, and they can also enhance the tolerance of PGC1α to oxidative stress, which not only maintains the energy balance but also provides a survival environment for tumor cells, thus affecting the therapeutic effect (15). Here, BRAF is linked to neoplasm.